We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AbbVie Must Pay $3 Million in Retrial of First AndroGel Bellwether Suit
AbbVie Must Pay $3 Million in Retrial of First AndroGel Bellwether Suit
In a retrial, a jury ordered AbbVie to pay more than $3 million to a plaintiff who blamed his heart attack on misrepresentation of the risks posed by AbbVie’s testosterone replacement drug AndroGel.